Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable.
What changes if the standard account of Semaglutide and gastric emptying is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
The opening post is right about the mechanism and I think understates the practical bit.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
I have said this before in a thread nobody could find, so it is worth repeating.
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.
I had written a reply contradicting post #3 and deleted it. Here is what survived.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Posted with less confidence than the sentence structure implies.
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
Reading it back, the second half matters more than the first.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
It cost nothing to check and would have cost something not to.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…
|
+58 | 62 | 49k | 20mo |
|
Comparing the STEP programme populations: who was actually enrolled — the long version
On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. A narrow question about Comparing the STEP programme…
|
4 | 7.7k | 11mo | |
|
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a…
|
+42 | 46 | 1.7k | 5mo |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
|
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…
|
+61 | 65 | 1.3k | 22mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why a preprint's supplementary material is often the best part
Why a preprint's supplementary material is often the best part I have a specific reason for asking rather than idle curiosity, and the context is below. A question about how this site should cite something…
|
+38 | 42 | 863 | 22mo |
|
Coming back to: Prediction intervals and why they are more honest than confidence intervals
Prediction intervals and why they are more honest than confidence intervals Writing it up because I had to work it out twice and would rather nobody else did. Prediction intervals — I have the observation and…
|
2 | 65 | 22mo | |
|
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
|
+35 | 39 | 547 | 11mo |
|
Waist circumference technique and its repeatability
Waist circumference technique and its repeatability — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin waist circumference technique down and I want…
|
+55 | 60 | 11k | 5mo |
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
|
+149 | 159 | 30k | 15mo |